Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review
This systematic review aimed to compare the influence of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on the efficacy and safety of elderly patients with type 2 diabetes and younger individuals. A comprehensive search of PubMed, Embase, and Web of Science databases was conducted up to Septem...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Japan Endocrine Society
2024-06-01
|
| Series: | Endocrine Journal |
| Subjects: | |
| Online Access: | https://www.jstage.jst.go.jp/article/endocrj/71/6/71_EJ23-0384/_html/-char/en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591941757304832 |
|---|---|
| author | Yao Wang Jiangling Wang Qian Gong Haoming Wu Shuhao Yang Jufeng He Xulin Hu Tianfang Huang |
| author_facet | Yao Wang Jiangling Wang Qian Gong Haoming Wu Shuhao Yang Jufeng He Xulin Hu Tianfang Huang |
| author_sort | Yao Wang |
| collection | DOAJ |
| description | This systematic review aimed to compare the influence of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on the efficacy and safety of elderly patients with type 2 diabetes and younger individuals. A comprehensive search of PubMed, Embase, and Web of Science databases was conducted up to September 2022. The summary standard means difference and odds ratios were calculated. Thirteen articles were included in the analysis. The incidence of adverse events (AEs) leading to discontinuation was higher in elderly patients (OR = 0.67, 95% CI 0.47 to 0.96, p = 0.028). However, no significant differences were observed in weight loss (SMD = 0.03, 95% CI –0.12 to 0.19, p = 0.686), HbA1c% (SMD = –0.02, 95% CI –0.11 to 0.08, p = 0.715), FBG levels (SMD = –0.03, 95% CI –0.11 to 0.06, p = 0.537), and the incidence of overall AEs (OR = 0.85, 95% CI 0.71 to 1.01, p = 0.072), serious AEs (OR = 0.68, 95% CI 0.45 to 1.04, p = 0.077), nausea (OR = 0.91, 95% CI 0.81 to 1.03, p = 0.140), vomiting (OR = 0.95, 95% CI 0.79 to 1.13, p = 0.532), diarrhea (OR = 0.86, 95% CI 0.72 to 1.02, p = 0.081), and hypoglycemia (OR = 1.22, 95% CI 0.90 to 1.65, p = 0.193). In conclusion, while certain AEs leading to discontinuation may be more prevalent in older patients, GLP-1RAs are effective for weight loss and lead to decreased glucose concentrations with a low rate of complications in elderly patients. |
| format | Article |
| id | doaj-art-e40d728db6af4b08a476369d2f2d6e5b |
| institution | Kabale University |
| issn | 1348-4540 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | The Japan Endocrine Society |
| record_format | Article |
| series | Endocrine Journal |
| spelling | doaj-art-e40d728db6af4b08a476369d2f2d6e5b2025-01-22T05:07:43ZengThe Japan Endocrine SocietyEndocrine Journal1348-45402024-06-0171657158210.1507/endocrj.EJ23-0384endocrjEfficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic reviewYao Wang0Jiangling Wang1Qian Gong2Haoming Wu3Shuhao Yang4Jufeng He5Xulin Hu6Tianfang Huang7Clinical Medical College & Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, Sichuan, 610081, P.R. ChinaClinical Medical College & Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, Sichuan, 610081, P.R. ChinaClinical Medical College & Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, Sichuan, 610081, P.R. ChinaClinical Medical College & Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, Sichuan, 610081, P.R. ChinaClinical Medical College & Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, Sichuan, 610081, P.R. ChinaClinical Medical College & Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, Sichuan, 610081, P.R. ChinaClinical Medical College & Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, Sichuan, 610081, P.R. ChinaChengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, 610041, P.R. ChinaThis systematic review aimed to compare the influence of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on the efficacy and safety of elderly patients with type 2 diabetes and younger individuals. A comprehensive search of PubMed, Embase, and Web of Science databases was conducted up to September 2022. The summary standard means difference and odds ratios were calculated. Thirteen articles were included in the analysis. The incidence of adverse events (AEs) leading to discontinuation was higher in elderly patients (OR = 0.67, 95% CI 0.47 to 0.96, p = 0.028). However, no significant differences were observed in weight loss (SMD = 0.03, 95% CI –0.12 to 0.19, p = 0.686), HbA1c% (SMD = –0.02, 95% CI –0.11 to 0.08, p = 0.715), FBG levels (SMD = –0.03, 95% CI –0.11 to 0.06, p = 0.537), and the incidence of overall AEs (OR = 0.85, 95% CI 0.71 to 1.01, p = 0.072), serious AEs (OR = 0.68, 95% CI 0.45 to 1.04, p = 0.077), nausea (OR = 0.91, 95% CI 0.81 to 1.03, p = 0.140), vomiting (OR = 0.95, 95% CI 0.79 to 1.13, p = 0.532), diarrhea (OR = 0.86, 95% CI 0.72 to 1.02, p = 0.081), and hypoglycemia (OR = 1.22, 95% CI 0.90 to 1.65, p = 0.193). In conclusion, while certain AEs leading to discontinuation may be more prevalent in older patients, GLP-1RAs are effective for weight loss and lead to decreased glucose concentrations with a low rate of complications in elderly patients.https://www.jstage.jst.go.jp/article/endocrj/71/6/71_EJ23-0384/_html/-char/englucagon-like peptide-1 receptor agonists (glp-1ras)type 2 diabeteselderlyefficacysafety |
| spellingShingle | Yao Wang Jiangling Wang Qian Gong Haoming Wu Shuhao Yang Jufeng He Xulin Hu Tianfang Huang Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review Endocrine Journal glucagon-like peptide-1 receptor agonists (glp-1ras) type 2 diabetes elderly efficacy safety |
| title | Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review |
| title_full | Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review |
| title_fullStr | Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review |
| title_full_unstemmed | Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review |
| title_short | Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review |
| title_sort | efficacy and safety of glucagon like peptide 1 receptor agonists in the elderly versus non elderly patients with type 2 diabetes mellitus insights from a systematic review |
| topic | glucagon-like peptide-1 receptor agonists (glp-1ras) type 2 diabetes elderly efficacy safety |
| url | https://www.jstage.jst.go.jp/article/endocrj/71/6/71_EJ23-0384/_html/-char/en |
| work_keys_str_mv | AT yaowang efficacyandsafetyofglucagonlikepeptide1receptoragonistsintheelderlyversusnonelderlypatientswithtype2diabetesmellitusinsightsfromasystematicreview AT jianglingwang efficacyandsafetyofglucagonlikepeptide1receptoragonistsintheelderlyversusnonelderlypatientswithtype2diabetesmellitusinsightsfromasystematicreview AT qiangong efficacyandsafetyofglucagonlikepeptide1receptoragonistsintheelderlyversusnonelderlypatientswithtype2diabetesmellitusinsightsfromasystematicreview AT haomingwu efficacyandsafetyofglucagonlikepeptide1receptoragonistsintheelderlyversusnonelderlypatientswithtype2diabetesmellitusinsightsfromasystematicreview AT shuhaoyang efficacyandsafetyofglucagonlikepeptide1receptoragonistsintheelderlyversusnonelderlypatientswithtype2diabetesmellitusinsightsfromasystematicreview AT jufenghe efficacyandsafetyofglucagonlikepeptide1receptoragonistsintheelderlyversusnonelderlypatientswithtype2diabetesmellitusinsightsfromasystematicreview AT xulinhu efficacyandsafetyofglucagonlikepeptide1receptoragonistsintheelderlyversusnonelderlypatientswithtype2diabetesmellitusinsightsfromasystematicreview AT tianfanghuang efficacyandsafetyofglucagonlikepeptide1receptoragonistsintheelderlyversusnonelderlypatientswithtype2diabetesmellitusinsightsfromasystematicreview |